Devi SenGupta

5.5k citations

46 papers · 1.2k indexed · 1 hit paper · h-index 19

Impact in

Virology top 1%
- HIV Research and Treatment
Infectious Diseases top 2%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions

Papers in ⓘ

Virology 20
- HIV Research and Treatment 20
Infectious Diseases 26
- HIV/AIDS drug development and treatment 13
- HIV/AIDS Research and Interventions 8
- Tuberculosis Research and Epidemiology 4

Co-authors: Andrew Cheng (5 shared papers)Douglas F. Nixon (11 shared papers)Joseph M. Custodio (3 shared papers)Anton Pozniak (3 shared papers)Erin Quirk (4 shared papers)Steven G. Deeks (11 shared papers)Kirsten White (2 shared papers)Jihad Slim (3 shared papers)
Journals: Open Forum Infectious Diseases (5 papers)The Lancet HIV (4 papers)Journal of Virology (3 papers)The Journal of Immunology (3 papers)PLoS ONE (3 papers)
Partner nations: United States United Kingdom Spain

In The Last Decade

Devi SenGupta

44 papers receiving 1.2k citations

Hit Papers

align trajectories log scale

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial 2017 · 278 citations

Peers

Countries citing papers authored by Devi SenGupta

Since Specialization

Citations

This map shows the geographic impact of Devi SenGupta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Devi SenGupta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Devi SenGupta more than expected).

Fields of papers citing papers by Devi SenGupta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Devi SenGupta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Devi SenGupta. The network helps show where Devi SenGupta may publish in the future.

Co-authors

The 25 scholars most cited alongside Devi SenGupta, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Devi SenGupta Line = papers co-authored together Devi SenGupta links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 46 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial The Lancet ·Paul E. Sax, Anton Pozniak, Marisa Montes, Ellen Koenig, Edwin DeJesus, Hans-Jürgen Stellbrink, Andrea Antinori, Kimberly Workowski, Jihad Slim, Jacques Reynes, Will Garner, Joseph M. Custodio, Kirsten White, Devi SenGupta, Andrew Cheng, Erin Quirk Hit paper breakdown →	2017	278
2	Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment JAIDS Journal of Acquired Immune Deficiency Syndromes ·Anton Pozniak, José Ramón Arribas, Joseph Gathe, Samir K. Gupta, Frank A. Post, Mark Bloch, Anchalee Avihingsanon, Gordon Crofoot, Paul Benson, Kenneth Lichtenstein, Moti Ramgopal, Ploenchan Chetchotisakd, Joseph M. Custodio, Michael E. Abram, Xuelian Wei, Andrew Cheng, Scott McCallister, Devi SenGupta, Marshall W. Fordyce	2015	158
3	Heat Shock Protein-Mediated Cross-Presentation of Exogenous HIV Antigen on HLA Class I and Class II The Journal of Immunology ·Devi SenGupta, Philip J. Norris, Todd J. Suscovich, Mina Hassan‐Zahraee, Howell Moffett, Alicja Trocha, Rika Draenert, Philip Goulder, Robert Binder, Daniel L. Levey, Bruce D. Walker, Pramod K. Srivastava, Christian Brander	2004	63
4	Strong Human Endogenous Retrovirus-Specific T Cell Responses Are Associated with Control of HIV-1 in Chronic Infection Journal of Virology ·Devi SenGupta, Ravi Tandon, Raphaella G. S. Vieira, Lishomwa C. Ndhlovu, Rachel Lown-Hecht, Christopher E. Ormsby, Liyen Loh, R. Brad Jones, Keith Garrison, Jeffrey N. Martin, Vanessa A. York, Gerald Spotts, Gustavo Reyes‐Terán, Mario Ostrowski, Frederick Hecht, Steven G. Deeks, Douglas F. Nixon	2011	52
5	Multi-stakeholder consensus on a target product profile for an HIV cure The Lancet HIV ·Sharon R. Lewin, Timothy Attoye, Cathy Bansbach, Brian Doehle, Karine Dubé, Mark Dybul, Devi SenGupta, Adam Jiang, Rowena Johnston, Rosanne Lamplough, Joseph M. McCune, Gary J. Nabel, Thumbi Ndung’u, John C. Pottage, David H. Brown Ripin, James F. Rooney, Izukanji Sikazwe, Moses Supercharger Nsubuga, Mitchell Warren, Steven G. Deeks	2020	48
6	The CD8 ⁺ Memory Stem T Cell (T _SCM ) Subset Is Associated with Improved Prognosis in Chronic HIV-1 Infection Journal of Virology ·Susan Pereira Ribeiro, Jeffrey M. Milush, Edécio Cunha‐Neto, Esper G. Kallás, Jorge Kalil, Ma Somsouk, Peter W. Hunt, Steven G. Deeks, Douglas F. Nixon, Devi SenGupta	2014	44
7	Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials HIV Medicine ·D Hagins, Chloe Orkin, ES Daar, Anthony Mills, Cynthia Brinson, E DeJesus, Frank A. Post, Javier O Morales‐Ramirez, Melanie Thompson, Olayemi Osiyemi, Bruce Rashbaum, H‐J Stellbrink, Claudia Martorell, H Liu, Y‐P Liu, Danielle Porter, S. E. Collins, Devi SenGupta, Manika Das	2018	42
8	Trans-activation, post-transcriptional maturation, and induction of antibodies to HERV-K (HML-2) envelope transmembrane protein in HIV-1 infection Retrovirology ·Henri‐Alexandre Michaud, Miguel de Mulder Rougvie, Devi SenGupta, Steven G. Deeks, Jeffrey N. Martin, Christopher D. Pilcher, Frederick Hecht, Jonah B. Sacha, Douglas F. Nixon	2014	41
9	Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks Antimicrobial Agents and Chemotherapy ·Rima Acosta, Madeleine Willkom, Ross Martin, Silvia Chang, Xuelian Wei, William Garner, Justin Lutz, Sophia R. Majeed, Devi SenGupta, Hal Martin, Erin Quirk, Kirsten White	2019	41
10	Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study The Lancet HIV ·Edwin DeJesus, Moti Ramgopal, Gordon Crofoot, Peter Ruane, Anthony LaMarca, Anthony Mills, Claudia Martorell, Joseph de Wet, Hans‐Jürgen Stellbrink, Jean‐Michel Molina, Frank A. Post, Ignacio Valero, Danielle Porter, Ya-Pei Liu, Andrew Cheng, Erin Quirk, Devi SenGupta, Huyen Cao	2017	37
11	Bacteroides are associated with GALT iNKT cell function and reduction of microbial translocation in HIV-1 infection Mucosal Immunology ·Dominic Paquin‐Proulx, Christina B. Ching, Ivan Vujkovic-Cvijin, Douglas Fadrosh, Liyen Loh, Yong Huang, Ma Somsouk, Susan V. Lynch, Peter W. Hunt, Douglas F. Nixon, Devi SenGupta	2016	36
12	Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial The Lancet HIV ·Aditya H. Gaur, Hilda Kizito, Wasana Prasitsueubsai, Natella Rakhmanina, Mohammed Rassool, Rana Chakraborty, Jagmohan S. Batra, Pope Kosalaraksa, Wicharn Luesomboon, Danielle Porter, Yongwu Shao, Michael R. Myers, Lillian Ting, Devi SenGupta, Erin Quirk, Martin S. Rhee	2016	32
13	AIDS in India: recent trends in opportunistic infections. PubMed ·Sujaya Misra, Devi SenGupta, Sudhir Kumar Satpathy	1998	31
14	Identification of Human Endogenous Retrovirus-Specific T Cell Responses in Vertically HIV-1-Infected Subjects Journal of Virology ·Ravi Tandon, Devi SenGupta, Lishomwa C. Ndhlovu, Raphaella G. S. Vieira, R. Brad Jones, Vanessa A. York, Vinícius Vieira, Elizabeth R. Sharp, Andrew Wiznia, Mario Ostrowski, Michael Rosenberg, Douglas F. Nixon	2011	30
15	p16INK4a Expression and Immunologic Aging in Chronic HIV Infection PLoS ONE ·Susan Pereira Ribeiro, Jeffrey M. Milush, Edécio Cunha‐Neto, Esper G. Kallás, Jorge Kalil, Luiz Felipe Domingues Passero, Peter W. Hunt, Steven G. Deeks, Douglas F. Nixon, Devi SenGupta	2016	29
16	Anti-HERV-K (HML-2) capsid antibody responses in HIV elite controllers Retrovirology ·Miguel de Mulder Rougvie, Devi SenGupta, Steven G. Deeks, Jeffrey N. Martin, Christopher D. Pilcher, Frederick Hecht, Jonah B. Sacha, Douglas F. Nixon, Henri‐Alexandre Michaud	2017	24
17	Human Endogenous Retrovirus Expression Is Inversely Associated with Chronic Immune Activation in HIV-1 Infection PLoS ONE ·Christopher E. Ormsby, Devi SenGupta, Ravi Tandon, Steven G. Deeks, Jeffrey N. Martin, R. Brad Jones, Mario Ostrowski, Keith Garrison, Joel Armando Vázquez-Pérez, Gustavo Reyes‐Terán, Douglas F. Nixon	2012	22
18	Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial The Lancet HIV ·Joseph J. Eron, Jean‐Daniel Lelièvre, Robert C. Kalayjian, Jihad Slim, Anson K Wurapa, Jeffrey L. Stephens, Cheryl McDonald, Éric Cua, Aimee Wilkin, Brigitte Schmied, Mehri S. McKellar, Stephanie Cox, Sophia R. Majeed, Shuping Jiang, Andrew Cheng, Moupali Das, Devi SenGupta	2018	21
19	Cutting Edge: An Antibody Recognizing Ancestral Endogenous Virus Glycoproteins Mediates Antibody-Dependent Cellular Cytotoxicity on HIV-1–Infected Cells The Journal of Immunology ·Henri‐Alexandre Michaud, Devi SenGupta, Miguel de Mulder Rougvie, Steven G. Deeks, Jeffrey N. Martin, James J. Kobie, Jonah B. Sacha, Douglas F. Nixon	2014	19
20	Human scabies from contact with water buffaloes infested withSarcoptes scabieivar.bubalis Annals of Tropical Medicine and Parasitology ·Amalendu Chakrabarti, Anupam Chatterjee, Kunal Chakrabarti, Devi SenGupta	1981	17

About Devi SenGupta

Devi SenGupta is a scholar working on Virology, Infectious Diseases, Emergency Medicine, Immunology and Hematology, having authored 46 papers that have together received 1.2k indexed citations. Recurring topics across this work include HIV Research and Treatment (20 papers), HIV/AIDS drug development and treatment (13 papers), HIV/AIDS Research and Interventions (8 papers), HIV-related health complications and treatments (8 papers), Immune Cell Function and Interaction (6 papers), T-cell and B-cell Immunology (5 papers), Long-Term Effects of COVID-19 (4 papers) and Tuberculosis Research and Epidemiology (4 papers). The work is most often cited by research in Virology (507 citations), Infectious Diseases (728 citations), Emergency Medicine (278 citations), Immunology (186 citations) and Epidemiology (250 citations). Devi SenGupta has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Andrew Cheng, Douglas F. Nixon, Joseph M. Custodio, Anton Pozniak, Erin Quirk, Steven G. Deeks, Kirsten White, Jihad Slim, Edwin DeJesus and Ellen Koenig. Their work appears in journals such as Open Forum Infectious Diseases, The Lancet HIV, Journal of Virology, The Journal of Immunology and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact